Shanghai HeartCare Medical Technology Corporation Ltd (HeartCare) is a neuro-interventional medical device pioneer with the aim of redefining the therapeutic and preventive paradigm of stroke. It strives to reduce the mortality rate and improve prognosis of stroke in China and worldwide through the commercialization of its innovative product candidates.

According to China Stroke Statistics 2019, at least one in five deaths was caused by stroke in China. The ageing population has made the situation worse, making the country to have the highest rate of stroke risks among all countries in the world. In the meantime, the disability rate caused by strokes is high, but the window period for proper treatment is short. In the past, the stroke devices were mainly monopolized by international medical giants which made stroke treatment cost very high. For example, in 2019, the top five neuro-interventional medical device providers were all international companies, whose products accounted for 81.2% of the entire market share in China.

Since its establishment five years ago, HeartCare has developed a complete solution for stroke prevention and treatment, with five major products already commercialized in the market: intracranial stenosis treatment device, ischemic stroke treatment device, ischemic stroke thrombectomy device, hemorrhagic stroke treatment device and vascular access device.

In January 2020, HeartCare obtained NMPA registration certificates for its ExtraFlex distal access catheter, the first home-made device of its kind in the country, and SupSelek microcatheter. In August of the same year, its Captor thrombectomy device, the first domestic multi-markers thrombectomy stent retriever in China, obtained registration certificate. Up to date, in addition to its commercialized products, HeartCare is expected to commercialize nine currently late-stage product candidates in 2021 and 10 currently early-stage product candidates between 2022 and 2025, including the global first sirolimus intracranial drug-eluting balloon catheter for intracranial stenosis treatment, further expanding and diversifying its product offerings for the unmet and differentiated needs of stroke patients. In 2020, HeartCare spent 51.134 million yuan on R&D.

The HeartCare team has gained rich experience in coronary artery intervention product R&D and commercialization, and has the ability to quickly develop new products. Founder Wang Guohui has 16 years of experience in the R&D and commercialization of neurovascular and cardiovascular devices; Li Zhigang, head of the R&D team, has 25 years of experiences in the development of cardiovascular and cerebrovascular intervention devices; and marketing leader Zhang Ye has 20 years of clinical management experiences in the cardiovascular and cerebrovascular device market of the country.

By March 31, 2021, HeartCare had built a sales network consisting of 41 dealers, covering 1,135 hospitals in 25 provinces of the country. According to its IPO file, HeartCare recorded 13.619 million yuan in sales revenue in the first quarter of this year, close to its annual sales revenue in 2020.